PRAX

Business Context and Reporting Period

Company: Praxis Precision Medicines, Inc. (PRAX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Praxis is a clinical-stage biopharmaceutical company focused on central nervous system (CNS) disorders, specifically targeting neuronal excitation-inhibition imbalance. The company operates two proprietary platforms: Cerebrum (small molecules) and Solidus (antisense oligonucleotides). It has four clinical-stage product candidates: ulixacaltamide (Essential Tremor), relutrigine (Developmental and Epileptic Encephalopathies), vormatrigine (Common Epilepsies), and elsunersen (SCN2A-DEE).

Key Financial Metrics

Note: The filing text does not provide a specific "profit margin" as the company is pre-revenue and operating at a loss. Liquidity is supported by significant cash reserves and recent capital raises.

Material Changes vs. Prior Period

• Revenue Decline: Collaboration revenue dropped to zero in 2025 from $8.6 million in 2024. This was due to the completion of research service obligations under the UCB collaboration agreement in December 2024, after which UCB exercised its option to in-license rights.
• Expense Increase: Total operating expenses increased by $117.5 million (56%) year-over-year.
  • R&D Expenses: Increased by $114.7 million, driven primarily by the Cerebrum platform ($91.9 million increase). Key drivers included increased spend on the vormatrigine program (ENERGY studies), relutrigine program (EMBOLD/EMERALD trials and commercialization prep), and personnel-related costs.
  • G&A Expenses: Increased by $2.8 million, primarily due to higher professional fees and software costs.
• Capital Raising: The company significantly bolstered its liquidity through multiple financing activities in 2025, including a $567.1 million public offering in October 2025 and at-the-market offerings totaling $123.8 million. A subsequent $621.2 million public offering was completed in January 2026 (subsequent event).

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Commercialization Readiness: Praxis has submitted New Drug Applications (NDAs) to the FDA for ulixacaltamide (Essential Tremor) and relutrigine (SCN2A/SCN8A DEEs) following positive Phase 3 and Phase 2 registrational data, respectively. Commercial preparations are underway.
• Clinical Pipeline Progress:
  • Vormatrigine: Positive Phase 2 (RADIANT) results announced in late 2025. Phase 3 studies (POWER1, POWER2) are ongoing, with topline results expected in 2026 and 2027.
  • Elsunersen: Phase 3 registrational study (EMBRAVE3) is enrolling; topline results expected in 2027.
• Liquidity: Management expects cash, cash equivalents, and marketable securities as of December 31, 2025, combined with January 2026 proceeds, to fund operations into 2028.

Risks and Contingencies

• Regulatory Approval: No products are currently approved. Success depends on FDA/EMA approval of pending NDAs and future clinical trial outcomes.
• Capital Requirements: The company has incurred significant losses since inception and expects to continue doing so. Future funding may be required, potentially leading to dilution.
• Third-Party Dependence: Reliance on third-party manufacturers (CDMOs) and collaborators (e.g., Ionis, Tenacia) for development, manufacturing, and commercialization in certain regions.
• Intellectual Property: Risks related to patent expiration, enforcement, and potential infringement claims.

Key Facts for Investor Verification

• NDA Status: Verify the FDA's acceptance for filing and review timelines for the submitted NDAs for ulixacaltamide and relutrigine.
• Cash Runway: Confirm the burn rate and the sufficiency of the $926.1 million cash balance (plus Jan 2026 proceeds) to fund operations through 2028 without further dilution.
• Clinical Trial Data: Review the full clinical study reports for the Essential3 (ulixacaltamide) and EMBOLD (relutrigine) trials to assess the robustness of the data supporting the NDAs.
• Collaboration Milestones: Monitor potential future milestone payments and royalty obligations under agreements with Ionis, RogCon, and Tenacia, which could impact future cash flows.
• Patent Expirations: Review the specific expiration dates of key patents covering ulixacaltamide (expiring 2029-2045) and relutrigine/vormatrigine (expiring 2037-2043) to assess market exclusivity duration.